Page 5 - Repligen Corp News Today

Repligen Co. (NASDAQ:RGEN – Get Rating) – Research analysts at SVB Leerink lowered their Q4 2023 earnings per share estimates for Repligen in a note issued to investors on Tuesday, May 2nd. SVB Leerink analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.63 for the quarter, down from […]

Gulf International Bank UK Ltd bought a new stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 10,515 shares of the biotechnology company’s stock, valued at approximately $1,780,000. A number of other hedge funds and other institutional […]

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,431 shares of the biotechnology company’s stock, valued at approximately $2,662,000. Other large investors also recently added […]

Repligen (NASDAQ:RGEN – Get Rating) had its price objective reduced by Deutsche Bank Aktiengesellschaft from $180.00 to $165.00 in a research report sent to investors on Wednesday, The Fly reports. Other equities research analysts have also recently issued reports about the stock. Benchmark reduced their price target on shares of Repligen from $230.00 to $210.00 […]

Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by research analysts at Deutsche Bank Aktiengesellschaft from $180.00 to $165.00 in a report issued on Wednesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 4.94% from the company’s current price. RGEN has been the subject of several other reports. […]

Repligen (NASDAQ:RGEN – Get Rating) had its price target decreased by Craig Hallum from $220.00 to $207.00 in a report released on Wednesday, The Fly reports. Craig Hallum’s target price points to a potential upside of 31.65% from the stock’s current price. Several other research analysts have also recently commented on the company. SVB Leerink […]

Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair reduced their Q3 2023 earnings estimates for Repligen in a research report issued on Wednesday, May 3rd. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.52 per share for the quarter, down from their prior forecast […]

Repligen (NASDAQ:RGEN – Get Rating) issued its quarterly earnings data on Tuesday. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05, Briefing.com reports. Repligen had a return on equity of 10.31% and a net margin of 23.20%. The company had revenue of $182.70 million during the quarter, […]

Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by Stifel Nicolaus from $225.00 to $210.00 in a research note issued to investors on Wednesday, The Fly reports. A number of other brokerages also recently weighed in on RGEN. StockNews.com initiated coverage on Repligen in a report on Thursday, March 16th. They issued a […]

Repligen (NASDAQ:RGEN – Get Rating) updated its FY23 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.35-$2.42 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million. Wall Street Analyst Weigh […]